Arcoscreen

Arcoscreen is an early-stage biotech offering a unique GPCR screening service platform that operates directly on primary cells. Its core innovation combines a novel biological assay, which identifies the molecular mode of action (G protein involvement), with a custom microfluidic chip system that standardizes and miniaturizes the process. This approach aims to provide more physiologically relevant data earlier in drug discovery, potentially improving clinical predictability. The company is privately held, appears to be pre-revenue, and is led by a small, scientifically-focused team with expertise in microfluidics and GPCR biochemistry.

Arcoflow platform: A microfluidic chip-based system enabling GPCR drug screening and molecular mode of action (G protein coupling) identification directly in primary mammalian cells.

Arcoscreen competes in the drug discovery services and tools market. It differentiates itself by focusing specifically on GPCR mode-of-action analysis in primary cells via an integrated microfluidic platform. Competitors range from large CROs offering standard cell-based assays to other startups developing complex in vitro models (e.g., organ-on-a-chip). Its unique value is the combination of primary cells, G protein determination, and miniaturization.